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Abstract: Nodal status is one of the most important prognostic factors in breast cancer. 
Established tests such as touch imprint cytology and frozen sections currently used in the 
intra-operative setting show variations in sensitivity and specificity. This limitation has led 
to the development of molecular alternatives, such as GeneSearch, a commercial  
intra-operative real-time quantitative Polymerase Chain Reaction (RT-qPCR) assay that 
allows the surgeon to carry out axillary clearance as a one-step process. Since GeneSearch 
has been discontinued, we have developed the replacement Metasin assay, which targets 
the breast epithelial cell markers CK19 and mammaglobin mRNA and identifies metastatic 
disease in sentinel lymph nodes. The optimised assay can be completed within 32 min  
(6 min for RNA preparation and 26 min instrument run time), making its use feasible in the 
intraoperative setting. An analysis by Metasin of 154 archived lymph node homogenates 
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previously analysed by both parallel histology and GeneSearch showed concordance for 
148 cases. The sensitivity and specificity of Metasin compared with GeneSearch were 95% 
(CI 83%–99%) and 97% (CI 91%–99%) respectively; compared with histology they  
were 95% (CI 83%–99%) and 97% (CI 91%–99%), respectively. The sensitivity and 
specificity of GeneSearch compared with histology were 90% (CI 77%–96%) and 97%  
(CI 93%–99%) respectively. The positive predictive value of Metasin was 90% and 
negative predictive value was 98% for both histology and GeneSearch. The positive 
predictive value of GeneSearch was 92% and the negative predictive value was 97% 
compared to histology. The discordance rates of Metasin with both GeneSearch and 
histology were 3.89%. In comparison, the discordance rate of GeneSearch with  
histology was 4.5%. Metasin’s robustness was independently evaluated on 193 samples  
previously analysed by GeneSearch from the Jules Bordet Institute, where Metasin yielded 
comparable results. 
Keywords: Metasin; CK19; sentinel node; metastatic; GeneSearch; intra-operative; 
OSNA; NICE; Mammaglobin; Cepheid; qPCR; POC; breast; cancer; PBGD; axillary; 
immunostains; MGB 
 
1. Introduction 
The most important prognostic factor in breast cancer is the presence or absence of disseminated 
tumours in the axillary lymph nodes [1,2] and the spread of cancer to the sentinel lymph nodes, whilst 
not classifying the patient as having M1 disease, is indicative of a poorer prognosis. Hence the 
assessment of sentinel lymph node biopsies is the standard of care for staging the axilla [3–5], and its  
intra-operative examination offers the advantage of allowing an immediate axillary dissection of a 
positive node. This avoids the need for a second operation with its associated anxiety and risk to the 
individual patient, releases theatre time for more operations, cuts down on the demand for surgical 
beds and thereby, reduces costs to the National Health Service (NHS).  
However, conventional intra-operative methods, such as frozen section and touch cytology, are 
time- and labour intensive and have a wide range of sensitivity, ranging from 59% to 88.2% for frozen 
sections and from 40% to 58.3% for touch imprint cytology [6–8]. This has led to the evaluation of 
real time quantitative PCR (qPCR)-based methods, which are sensitive, specific, rapid, relatively 
inexpensive and can be automated, making their use in the intra-operative setting practical. 
Furthermore, whereas histology only assesses a representative section of the tissue and therefore 
introduces sampling error, qPCR analysis can potentially be carried out on the whole node for the 
presence of markers of interest. The GeneSearch BLNA assay (Veridex LLC, WARREN, NJ, USA) is 
a now discontinued commercial intra-operative qPCR assay that detected the presence of  
tumour-specific markers cytokeratin-19 (CK-19) and mammaglobin (MGB) in sentinel lymph  
nodes [5,9–11]. If either one or both of the markers were positive, the node was considered positive 
and an axillary clearance would be carried out. Porphobilinogen deaminase (PBGD) was used as a 
positive control for successful RNA extraction. Despite its proven clinical usefulness, preliminary 
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Federal Drug Administration (FDA) approval and use in the UK and Europe, the assay was withdrawn, 
mainly due to insufficient implementation in the US home market [12].  
Consequently, we set out to develop a replacement assay, termed Metasin, using the same markers, 
but with freely available commercial reagents and capable of running on any thermocycler. 
Importantly, publication of primer and probe details will enable biomedical scientists to optimise the 
assay within their own institutions. The primers and probe sequences, PCR master mixes and run 
conditions were optimised and the assay was validated to generate an assay that matched the 
performance of the GeneSearch assay [5,9–11]. This report compares the performance of the new 
Metasin assay with both conventional histological methods that provide a ‘gold standard’ as well as the 
GeneSearch assay for the assessment of archived lymph node lysates from a cohort of 154 cases.  
2. Results  
2.1. Patient Demographics 
Details listing the patient demographics and relevant clinical information were retrospectively 
collected and are presented in Table 1. No patient demographics were available for the samples from 
the Jules Bordet Institute (JBI).  
Table 1. Patient demographics and clinical information. 
 
Nodal status 
All 
patients 
Total  
Type of 
tumour 
Nodal status 
 
Total 
Patients Enrolled age, 
years  
156 
 
IDC 
positive SN 26 103 
negative SN 74 
mean age at diagnosis 
positive SN 60.2 62.2 
ILC 
discordant SN 3 
16 negative SN 63.2 positive SN 6 
discordant SN 60.2 negative SN 9 
median age at 
diagnosis 
positive SN 59 
63 Others 
discordant SN 1 
32 negative SN 63 positive SN 6 
discordant SN 62 negative SN 24 
age range  
positive SN 39–92 
34–92 DCIS 
discordant SN 2 
11 negative SN 34–87 positive SN 0 
discordant SN 43–68 negative SN 10 
Surgery Performed discordant SN 1 
Mastectomy 
positive SN 18 
42 LCIS 
positive SN 0 
1 negative SN 18 negative SN 1 
discordant SN 6 discordant SN 0 
Wide local excision 
positive SN 18 
100 
Hormone 
receptor status discordant SN 0 negative SN 17 
Tumour Size (TNM) 
(15)     
discordant SN 0 
 
pT1 (<2 cm) 
positive SN 18 
79 Mean ER score 
positive SN 7 
7 negative SN 61 negative SN 6 
discordant SN 0 discordant SN 7 
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Table 1. Cont. 
 
Nodal status 
All 
patients 
Total Type of tumour Nodal status   Total 
pT2 (>2 cm, <5 cm) 
positive SN 15 
46 PR positive 
positive SN 27 
103 negative SN 28 negative SN 71 
discordant SN 3 discordant SN 5 
pT3 (>5 cm) 
positive SN 2 
4 PR negative 
positive SN 10 
45 negative SN 2 negative SN 34 
discordant SN 0 discordant SN 1 
Tumour Grade Mean PR score positive SN 6 5 
Grade 1 
positive SN 5 
20 
negative SN 5 
negative SN 15 
Her2 positive 
discordant SN 5 
discordant SN 0 positive SN 4 13 
Grade 2 
positive SN 20 78 
Her2 negative 
negative SN 8 
negative SN 55 discordant SN 1 
discordant SN 3 positive SN 33 127 
Grade 3 
positive SN 12 29 
Triple negative 
negative SN 90 
negative SN 16 discordant SN 4 
discordant SN 1 positive SN 1 14 
Ungradeable 
positive SN 0 10 negative SN 13 
negative SN 9 discordant SN 0 
discordant SN 1 
2.2. Characteristics of the PCR Assay 
Metasin PCR efficiencies for CK19, MGB and PBGD-specific were 97.3%, 100% and 100%, 
respectively (results not shown). A comparison of amplification reactions carried out as either 
monoplex and multiplex reactions resulted in an average difference in quantification cycle (ΔCq) of 
1.5, suggesting little interference between the nine primer/probe combinations. Analysis of PCR 
products on agarose gels resulted in single bands of the expected size and the absence of smearing, 
indicating an optimised PCR reaction (Figure S1). Since pseudogenes are known to exist for CK19, its 
sequence was aligned with those of the pseudogenes, demonstrating the specificity of the primer and 
probe used (Figure S2). Absence of pseudogene amplification was also demonstrated empirically by 
using DNA from 100 colon tumours as templates in the Metasin PCR reaction. No amplification 
signals were detected in either the CK19 or MGB reactions and the fluorescence detected in the PBGD 
reaction was below the cut-off threshold established previously. Gel electrophoresis of the PCR 
reactions showed a series of smears (results not shown).  
2.3. Cut-Off Values for Positive and Negative Nodes and Macro- and Micro-Metastases 
Once all concordant positive cases were identified, histology and GeneSearch results were used to 
group the nodes into macrometastases and micrometastases (Figure 1). Extrapolation from the 
scatterplot identified cut-off quantification cycle (Cq) values for positive and negative nodes as ≤32 for 
CK19 and ≤32.3 for MGB. The cut-off Cq values for macrometastases were identified as ≤25 for 
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CK19 and/or ≤26 for MGB. The cut-off Cq values for micrometastases were identified as between 
25.1 and 32 for CK19 and/or between 26.1 and 32.3 for MGB. This is similar to the GeneSearch 
criteria, that record macrometastases as having a Cq value of <25 for CK19 and <26 for MGB, with 
micrometastases having Cq values between 25 and 30 for Ck19 and 26 and 31 for MGB [5,9–11]. The 
standard histological criteria for reporting of macrometastases are tumour deposits greater than 2 mm 
and for micrometastases between 0.2 and 2 mm [13–15]. 
2.4. Comparison of Metasin with Histology 
A total of 350 nodes from 154 cases were tested using Metasin and compared with histology 
(Tables 2 and 3). 37 cases (24%) containing 61 positive nodes were positive for both Metasin and 
histology. Of these, 50 (81.9%) were macrometastases and eight (13%) micrometastases by both 
Metasin and histology (Table 4). Three nodes were positive overall but with differing tumour volumes 
(Table 4). 111 cases (72%) containing 280 nodes were negative for both.  
There were initially 10 (6.49%) discordant cases (Table 2, upper panel). Eight were false positives, 
defined as histology-negative and Metasin-positive (H− M+) and two were false negatives, defined as 
histology-positive and Metasin-negative (H+ M−). 
An additional histological assessment of the eight false positives at deeper levels and staining with 
MNF116, a pancytokeratin marker, revealed four to be positive showing micrometastases, reducing the 
number of false positive discordant cases to four (see Table 2, lower panel). When the four cases with 
micrometastases on deeper levels were tested with GeneSearch, three also tested positive but one  
was negative. 
Table 2. Discordant analysis and case-based outcome after deeper levels. 
Concordant cases Discordant cases Total Discordant cases 
H+ M+ H− M− H+ M− H− M+ 
Initial analysis 33 (21.4%) 111 (7.2%) 2 (1.3%) 8 (5.2%) 154  10 (6.49%) 
Deeper levels  37 (24%) 111 (77%) 2 (1.3%) 4 (2.6%) 154 6 (3.89%) 
H = Histology, M = Metasin: + = positive and − = negative. 
Table 3. Results of Metasin for cases and nodes compared with GeneSearch A (left) and 
Histology (right). 
Metasin vs. GeneSearch A Metasin vs. Histology 
Node Based-Analysis Node Based-Analysis 
Positive nodes 64 (18.2%) Positive nodes 61 (17.4) 
Negative nodes 280 (80%) Negative nodes 280 (80%) 
Discordant nodes 6 (1.7%) Discordant nodes 9 (2.5%) 
Total 350 Total 350 
Case Based-Analysis  Case Based-Analysis  
Positive patients 37 (24%) Positive patients 37 (24%) 
Negative patients 111 (72%) Negative patients 111 72% 
Discordant patients 6 (3.89%) Discordant patients 6 (3.89%) 
Total 154 Total 154 
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Table 4. Comparison of tumour volumes in concordant positive nodes between Metasin 
and histology (n = 61). 
Metasin Total 
Histology Macro Micro  
Macro 50 (81.9%) 2 (3.2%) 52 (85.2) 
Micro 1 (1.6%) 8 (13%) 9 (14.7) 
Total 51 (84%) 10 (16.4%) 61 (100%) 
The Metasin assay was rerun on the two false negative (H+ M−) cases and both were found to be 
consistently negative for Metasin (Table 2). When tested with GeneSearch, one of these tested positive 
the other negative; further descriptions of these two cases are provided in the discussion section. The 
overall case-based discordant rate after discordance is 3.89 percent (Tables 2 and 3). 
Consequently, the sensitivity of Metasin compared with histology is 95% (37/39, 95% CI  
83%–99%) and the specificity is 97% (CI 91%–99%). The discordance rate of Metasin compared with 
histology is 3.89%. Metasin has a positive predictive value (PPV) of 90% and a negative predictive 
value (NPV) of 98%. The sensitivity of GeneSearch compared with histology is 90% (77%–96%,  
95% CI) and its specificity is 97% (CI 93%–99%), PPV is 92% and NPV is 97%. The discordance rate  
is 4.5%. 
2.5. Comparison of Metasin with GeneSearch  
A total of 350 nodes from 154 cases were assessed using Metasin and GeneSearch. 37 cases (24%) 
containing 64 positive nodes were either positive for both CK19 and MGB or for one or the other 
(Tables 3 and 5). 111 cases (72%) containing 280 nodes were negative for both markers. Six cases 
(3.89%) were discordant, i.e., the result of both assays did not match (Table 3). Four of those cases 
were Metasin-positive and GeneSearch-negative and two cases were Metasin-negative and  
GeneSearch-positive. Histological analysis of deeper levels revealed micrometastases in 3/4 cases, 
reinforcing the validity of the Metasin result (see Tables 3 and 5). Consequently, Metasin has a 
sensitivity of 95% (37/39, 95% CI 83%–99%) and a specificity of 97% with a discordance rate of 
3.89%. Metasin has a PPV 90% and a NPV of 98%.  
Table 5. Discordant results between Metasin and GeneSearch A. 
Node based discordance 
Concordant  Discordant  Total Discordant nodes 
1 G+ 2 M+ G− M− G+ M− G− M+ 
64 (18.2%) 280 (80%) 2 (0.6%) 4 (1.14%) 350  6 (1.17%) 
Case based discordance 
Concordant  Discordant  Total Discordant cases 
G+ M+ G− M− G+ M− G− M+ 
37 (24%) 111 (72%) 2 (1.2%) 4 (2.6%) 154  6 (3.89%) 
1 G = GeneSearch A, 2 M = Metasin: + = positive and - = negative. 
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Figure 1. Determining the cut-off Cq values for positive and negative nodes and macro 
and micro metastases. (A) & (B) Scatter plots of Cq values GeneSearch data points (x-axis) 
compared to that obtained with Metasin (y-axis) for A: CK19 and B: MGB; (C) Scatter 
plot of Cq values obtained with Metasin Cq values for CK19 and MGB are illustrated in 
the x and y axis respectively. The numbers denote the Cq values obtained from the Cepheid 
Smart Cycler after 36 cycles by Metasin. The data points representing Cq values for nodes 
within the blue shaded area represent macros by Metasin, whilst data points in the clear 
region are micros by Metasin. Cq values in the yellow shaded area are negative or 
represent isolated tumour cells. The black data points represent nodes that are macros by 
both histology and GeneSearch (n = 47). The orange data points represent concordant 
micros by both histology and GeneSearch (n = 5). The red data points represent discordant 
histologically negative nodes that were scored as micro (n = 7, red circles) and macro  
(n = 2, red crosses) by GeneSearch. The inset shows the Cq cut off values for macro and 
micros by Metasin for CK19 and MGB. 
 
 
Figure 1 illustrates the distribution of Cq values obtained from the GeneSearch assay compared to 
Metasin. The individual Cq values for the predictive markers CK19 and MGB are presented in  
Figure 1A–C is a scatterplot of the distribution of Cq values for CK19 and MGB data obtained by 
Metasin, colour-coded and categorised as per macro-or micrometastasis by GeneSearch and histology. 
The scatterplot clearly illustrates the validity of the Metasin positive/negative and macro/micro Cq cut 
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offs. Further description and discussion of the discordant nodes are available in the Table S1 and 
discussion sections, respectively. 
2.6. Statistical Analysis: Comparison of Cq Values of Metasin with GeneSearch 
In the positive node group, there was significant correlation between GeneSearch and Metasin for 
PBGD (rho = 0.499, p < 0.0001), CK19 (rho = 0.248, p = 0.041) and MGB (rho = 0.653, p < 0.0001). 
In the negative node group, there was significant correlation between GeneSearch and Metasin for 
PBGD (rho = 0.271, p < 0.0001) and MGB (rho = 0.471, p < 0.0001) but no significant correlation for 
CK19 (rho = –0.035, p = 0.567). Isolated tumour cells (ITCs) are considered negative and have a Cq 
value above the cut-off. The inclusion of this data impacts on the overall correlation for the negative 
node group and is most evident for CK19.  
2.7. Independent Verification of Positive/Negative Macro/Micro Cut-Offs for Metasin  
RNA obtained from the JBI provided the opportunity to further refine the methodology and test the 
validity of the assay and cut offs. RNA samples from 193 anonymised (blinded to results) nodes were 
obtained. RNA had previously been prepared from these nodes as per GeneSearch protocol and 
assessed using the GeneSearch assay. Results were locally collated after re-analysis of these RNA 
samples on the Metasin assay. Table 6 and Figure 2A–C summarise the outcome for these samples. Of 
the 56 (29%) nodes categorised as macrometastases by GeneSearch, all were also correctly identified 
by Metasin. However, Metasin returned a negative result for 15 of the 33 nodes classified as 
micrometastases by Genesearch. These were mainly at the cusp of the micrometastasis/negative 
interface and generated Cq values 0.1 to 1.1 Cq from the cut-off boundary with the exception of one 
node, where the ΔCq was 2.1 between GeneSearch and Metasin (results not shown). All 104 (53.9%) 
nodes negative by Genesearch remained negative. The scatterplot illustrates CK19 and MGB Cq 
values obtained for GeneSearch compared with Metasin (Figure 2A,B). There is a significant level of 
correlation for CK19. For MGB, RNA samples tended not to show a linear relationship beyond a Cq 
value of 35.  
Table 6. Summary of Metasin analysis of Jules Bordet Institute (JBI) GeneSearch assayed 
lymph nodes. 
 Genesearch analysed nodes from JBI 1 Total 
 Macro-Metastasis 1 Micro-metastasis Negative Nodes  
Metasin Positive 
Nodes 2 
56 (29%) 18 (9.3%) – 74 (38.3%) 
Metasin Negative 
Nodes 
– 15 (7.7%) 104 (54%) 119 (61.7%) 
Total 56 (29%) 33 (17.1%) 104 (53.9%) 193 (100%) 
1 Genesearch based macro/micro cut offs were defined as CK19 < 25 for macro-metastasis and less than 30 
for micro-metastasis. MGB < 26 for macro-metastasis and less than 31 for micro-metastasis. 2 Metasin cut 
offs were defined as CK19 < 25 for macro-metastasis and less than 32 for micro-metastasis. MGB < 26 for 
macro-metastasis and less than 32.3 for micro-metastasis. 
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Figure 2. Comparison of Cq Values for GeneSearch vs. Metasin for JBI Samples. The  
scatter-plots illustrate Cq values for sentinel lymph node RNA samples examined by the 
Metasin assay. These results were compared to data obtained using GeneSearch A.  
(A) CK19 Cq values obtained for GeneSearch A plotted against the values for Metasin;  
(B) MGB Cq values obtained for GeneSearch A plotted against the values for Metasin;  
(C) The illustration shows the Cq values for Metasin determined CK19 (x-axis) versus 
MGB (y-axis). The coloured data points represent the differing combinations of the 
outcome for these nodes determined by Metasin. The Cq value cut-offs (indicated by solid 
lines) determined empirically for Ck19: Macros were less than 25 and micros more than 25 
and less than 32: MGB Macros less than 26 and micros more than 26 and less than 32.3. 
The yellow shaded area (top right) represents nodes determined to be negative and the clear 
area represents micros as determined by Metasin. Nodes determined by GeneSearch as 
macros are illustrated as red data points and micros as black data points respectively. 
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The scatterplot in Figure 2C shows the distribution of the Cq values for CK19 and MGB data 
obtained by Metasin categorised as macro- or micrometastasis by previous GeneSearch analysis. The 
scatterplot clearly illustrates the validity of the Metasin positive/negative and macro/micro Cq cut offs.  
2.8. Statistical Analysis of JBI Samples 
JBI samples were analysed using the same statistical methods, comparing GeneSearch and Metasin 
Cq values for positive and negative node groups for CK19, MGB and PBGD.  
Using the Spearman’s correlation test, there was significant correlation within the positive group 
between GeneSearch and Metasin for CK19 (rho = 0.842, p < 0.0001) and MGB (rho = 0.454,  
p < 0.0001) but no significant correlation for PBGD (rho = 0.177, p = 0.101). In the negative group, 
there was significant correlation for PBGD (rho = 0.383, p < 0.0001) and MGB (rho = 0.804,  
p < 0.0001), but there was no significant correlation for CK19 (rho = 0, p = 0.997).  
2.9. CK19 and MGB IHC  
All needle cores of the primary tumours analysed in the retrospective cases at Harlow (n = 154) 
were stained for CK19 and MGB and evaluated for staining characteristics. These cores were scored 
positive or negative. Consensus was universal except in 3 cases where there was arbitration by a third 
pathologist. Two cases failed to show tumours in the material submitted for immunostaining. Of the 
remaining cases (n = 152), 151 showed CK19 immunoreactivity. Conversely, only 86 of 152 cores 
(57%) showed MGB immunoreactivity. In two cases where the core biopsies showed intense  
immuno-reactivity for CK19, RNA from the matched positive lymph node failed to amplify for CK19 
but Cq values for MGB were in the range characteristic for micrometastases.  
Limits of the Detection of Metasin: Copy Number and Cell Count Number Determination 
The experiments were carried out at five different time points and doubling dilutions of RNA were 
used in the Metasin assay. Figure 3A illustrates a consistent linear relationship of “cell counts” to Cq 
value up to a Cq value of 27. Thereafter, the linear relationship between Cq value and cell count drift. 
Furthermore, up to this point the spread of Cq values for each of the 5 data points per dilution is of the 
order of 1 Cq value. Thereafter, the 5 repeated data points show a spread of 1.5 Cq points to 2.9 Cq 
points, reinforcing the lack of linearity at further dilutions of the cell line RNA. At 500-cell 
equivalence only one of five PCR reactions yields any signal. If this were extrapolated to the clinical 
scenario, then this would correspond to a detection capability of at least 1000 cells. Attempts to 
reproduce the doubling dilutions of MCF7 cells in normal lymph node homogenates failed to yield any 
meaningful results.  
Cloned plasmids were separately diluted in 10 fold dilutions and evaluated on the Metasin assay. 
The copy numbers were plotted against Cq values corresponding to the dilution (Figure 3B).  
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Figure 3. Metasin CK19 Cq values Cell Counts and copy numbers of plasmid. (A) The 
scatter plot illustrates the spread of Cq values in relation to the number MCF7 Cells 
harvested and examined by the Metasin assay. The data points correspond to cells 
harvested at 1 × 106 cells. Doubling dilutions of RNA were prepared prior to Metasin. The 
x-axis shows the number of cells corrected for RNA dilutions corrected for number of cells 
in the diluted RNA samples. The vertical dotted line at 200 cells corresponds to presumed 
isolated tumour cell burden (ITCs) and the solid black line demarcates the boundary 
between Micro-metastasis and macro-metastasis tumour burden in the assay; (B) cDNA 
fragments cloned into plasmids prepared by TIBMOL BIOL were diluted at 10 fold 
dilutions and analysed by Metasin A. Cp values obtained (y-axis) are presented against 
dilutions. PBGD plasmid dilutions are green, CK19 red and MGB Blue. 
 
3. Discussion 
We describe the initial evaluation of Metasin in parallel with GeneSearch and compared with the 
benchmark histological assessment. The Metasin assay has many similarities to the withdrawn GeneSearch 
test, with a similar RNA preparation protocol and choice of predictive markers. It is fast, inexpensive, 
but can use any qPCR platform, unlike GeneSearch testing, which is software-limited to the Cepheid 
Smartcycler. Furthermore, in contrast to the commercial assay, we are reporting the primer and probe 
sequences, so allowing interested laboratories to reproduce and utilise this new assay. The assay’s high 
sensitivity, specificity and most importantly, capacity to deliver a result in less than 32 min makes it fit 
for the purpose of application in the intra-operative setting. Furthermore, since results appear in  
real-time, positive results can be reported as soon as the characteristic amplification plots appear.  
Metasin makes use of the same strategy as the GeneSearch assay by including two markers for the 
prediction of metastatic disease, CK19 and MGB and reporting a positive result if both or either of the 
two markers generate amplification products. Published data [16,17] suggest that 98% to 99% of breast 
tumours are CK19 positive and extrapolate that the lymph node metastasis from these cases are also 
likely to be CK19 positive. However, no published data exist that correlate the immunohistochemistry 
data in the core biopsy or lymph node with the expression of CK19 at the RNA level. Hence it is 
interesting that during the development of the assay we scored 10% of cases with lymph node 
metastasis as CK19 negative at the RNA level. Fortunately, these cases were detected by both 
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molecular tests since they were all positive for MGB. Two of these cases showed intense CK19 
positivity by immunostaining of the core biopsies. These observations challenge the supposition that it 
is important to assess CK19 immunostaining of core biopsies for sentinel lymph node analysis [16,17]. 
Clearly, the use of molecular tests targeting CK19 only carries the clinical risk of missing  
nodal metastasis. 
Assays targeting the CK19 gene can result in false positive results due to inadvertent amplification 
of CK19 pseudogenes, genomic DNA sequences similar to CK19 but not specifying translation 
products [18]. Traces of DNA that remain in RNA preparations can serve as templates for 
amplification with insufficiently validated primers, which are then detected with probes that are not 
sufficiently specific. Our approach essentially eliminates the risk of pseudogene amplification at two 
levels: (i) CK19 primer alignment shows several mismatches with both the forward and reverse primer 
binding sequences, making successful amplification of pseudogenes at the optimised annealing 
temperatures highly unlikely (see supplementary Figure provided); (ii) the detection probe also has a 
number of mismatches with pseudogene target sequences. Hence, even if a pseudogene were to be  
inadvertently amplified, the misamplified PCR amplicons would not be reported at the fluorescence 
detection temperature.  
This was confirmed empirically in three ways: 
1. amplification products run on agarose gels showed only a single band of the correct size  
(128 bp).  
2. amplification of 100 DNA samples with the Metasin assay did not result in any detectable 
fluorescence signals and gel electrophoresis of amplified material yielded a series of smears.  
3. We draw on our observations relating to the low discordant rates of the Metasin assay having 
analysed over 1700 cases maintaining an overall discordant rate under 4 percent.  
Benchmarking the Metasin against the GeneSearch assay clearly demonstrates equivalence of 
results in most cases. Discrepancies of micrometastasis detection are probably accounted for by 
variable RNA degradation of the samples obtained from the JBI, which had been stored at −80 °C for 
more than two years and were used to validate the Metasin assay independently and blinded against the 
GeneSearch test. Our data reveal a discordance level of 3.98% between Metasin and histology, with a 
similar level (4.5%) of discordance observed for GeneSearch compared to histology. This is lower than 
previously reported discordance rates of intraoperative testing using qRT-PCR of up to 7% [5,9–11]. 
We have recently completed the validation of this assay in a much larger cohort of cases and 
demonstrate a discordance rate comparable to that reported here of <4% and the assay is now CE 
marked and available for general use (manuscript in preparation).  
Although in diagnostic terms histopathology continues to be the gold standard, it has its limitations. 
A routine histopathological analysis usually analyses only a 3 μM slice from a wedge of tissue  
2000 μM thick; the rest remains unexamined in the paraffin block. Consequently, an examination of 
sentinel nodes will detect metastases only if tumour is present in that particular 3 μM section. 
Furthermore, some histological subtypes (lobular carcinoma) are refractory to detection by the naked 
eye, leaving diagnosis dependent on detection by immuno-staining for cytokeratin [19]; hence 
guidelines for breast-cancer-reporting now mandate the use of immunohistochemistry [20].  
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To be absolutely certain of the absence of tumour in a lymph node, over 600 3 μM H & E stained 
sections would need to be carried out through a typical 2 mm lymph node slice [21]. This is clearly 
impractical, hence the compromise of examining the lymph nodes at three levels (three level, best 
practice) instead of examining one slide (single level analysis). Even then, this provides only a  
“snap-shot” view and most of the original 2 mm thick tissue will remain unexamined in the histology 
block, making the “gold standard” histological assessment rather inadequate.  
Validation studies need to be bench-marked against current practice, which means single level 
histopathology of sentinel lymph nodes. Hence, alternative slices of serially sectioned lymph nodes 
were submitted for histology and for molecular analysis. Although examination of lymph nodes at 
three levels is adequate for most instances, it is not where “disease” is focal. Hence, given the focal 
nature of metastatic disease in lymph nodes, the separation of the segments makes some discordance 
between histology and molecular analysis inevitable. For example, one of the cases illustrated here 
shows a 2.1 mm macrometastasis that was missed by both Metasin and by GeneSearch. Examination 
of multiple levels revealed this to be focal disease with a macro-metastasis present in the horizontal 
plane, which cuts out after the examination of 2 levels (300 μM) and is not present in the third level.  
Unlike PCR-based assays for sentinel node assessment, the OSNA assay available for intraoperative 
testing of sentinel nodes advocates the use of the whole node [22]. Here, we have demonstrated that 
the molecular approach can theoretically detect the presence of 500 to 1000 cells in lymph node 
homogenate without being subject to visual interpretive bias. Hence there is a rational argument for 
using the whole node for molecular analysis. However, this leaves no reserve material available for 
review and so requires any molecular assay to be utterly reliable. Metasin failed to detect three  
macro-metastasis (see Table provided in supplementary data), two of which also tested negative by the 
Genesearch test, suggesting that this discordance was due to allocation bias (see Table provided in 
supplementary data) and that the assays would have detected the tumour had the whole node been 
analysed. One was detected by the Genesearch assay, with the reason for this discrepancy unclear. 
Assay failure occurs in around 1.5% of cases (manuscript in preparation) and there is a rare theoretical 
risk of false positives due to the presence of epithelial inclusions [23,24] or the expression of CK19 in 
some high-grade lymphomas [25,26]. Clearly, these limitations must be highlighted in guidance notes 
to clinicians.  
The sensitivity of the assay was determined by using doubling dilutions of cell line RNA or plasmid 
DNA, since the control MCF7 cell line expresses only CK19 and PBGD, but not MGB. The assay is 
capable of detecting as few as 200 cell equivalents of RNA, although, this is not consistently 
reproduced. The significance of these observations is that ITCs are estimated to be of the order of 200 
to 500 cells since counts more than this most likely represent micro-metastasis [5,27,28]. 
4. Experimental Section 
4.1. Ethical Approval/PAH Samples 
This study was ethically approved by the Essex 2 Research Ethics Committee (Ethics Approval 
Reference: 07/H0302/129 & REC 10/H301/24). All patients undergoing sentinel lymph node biopsy 
for breast cancer during March 2008 to July 2010 at PAH were consented for their sentinel lymph node 
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tissue to be tested using the GeneSearch and Metasin tests. The inclusion criteria for participants 
included those undergoing a surgical excision of a primary operable breast cancer and sentinel lymph 
node sampling. No exclusion criteria were named. The patients were operated on by surgeons after the 
implementation of the “NEW START” program [4]. The results of primary data relating to the 
GeneSearch and the histology were known to the operators before validating the assay.  
4.2. Histopathological Processing and Assessment of Sentinel Lymph Nodes  
The sentinel lymph nodes were identified by a combined technique of radioactive (TcM99m) 
labelled nanocolloid and 2 mL of diluted Patent V blue dye [29]. Excess fat was removed from the 
lymph nodes and they were sliced into 2 mm sections with alternate slices allocated to 
Genesearch/Metasin and histology assessment. Slices for histology were processed individually 
according to local histology protocol and involved cutting five levels of 100 μM each together with 
three unstained serial sections per level. The slides were examined by two experienced Consultant 
Histopathologists and discordant node analysis included examination of a further five levels with 
immunostaining for MNF116 [30].  
4.3. Node Processing for GeneSearch/Metasin 
RNA extractions of the sentinel lymph node slices were carried out using a locally modified 
protocol of Qiagen’s RNeasy mini RNA extraction kit. The lymph node weight used for the RNA 
extraction step is the most critical parameter and it was essential to use the exact volume of 
homogenisation buffer [31]. The weight of each lymph node was determined very precisely, with the 
same amount used for every extraction. Tissue was homogenised in 400 μL Buffer RLT, an equal 
amount of 70% ethanol was added to the homogenised tissue, the tubes were vortexed briefly and the 
homogenate-ethanol mixture was added to RNeasy mini columns attached to a vacuum. Following 
several washes in proprietary Qiagen buffers, the RNA was eluted in 50 μL of RNAse-free water by 
spinning the columns in a microfuge at 10 × G for 1 mine.  
4.4. Ethical Approval/JBI RNA  
NREC project REC 10/H301/24 covered ethical approval for RNA obtained from the JBI. Stored 
frozen (−80 °C) RNA from 193 nodes were obtained retrospectively. These had been analysed 
previously using the GeneSearch assay, which recorded 104 nodes as negative and 89 as positive. The 
demographic details, histological outcome and axillary clearance data for this grouping were 
incomplete. The operators were blinded to the results of the original GeneSearch assay, which were 
provided after conclusion of the analysis. 
4.5. Quantitation and Identification of Template (RNA and DNA) 
A Nanodrop microvolume spectrophotometer (Thermo Scientific, Wilmington, DE, USA) was used 
to quantify all RNA samples. Purity was assessed using 260/280 ratios and, in addition, the RNA 
quality of a selection of random samples was assessed using a Bioanalyzer 2100 (Agilent, Stockport, UK). 
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4.6. Primer and Probe Sequences 
Target sequences for PBGD (NM_000190), CK19 (NM_002276) and MGB (NM_002411) were 
obtained from the National Centre for Biotechnology Information (NCBI) GenBank sequence database 
(http://www.ncbi.nlm.nih.gov/genbank/). qPCR amplification primers and hydrolysis probes were 
designed by a specialist oligonucleotide supply company (TIB Molbiol, Berlin, Germany) (Table 7). 
All primers were located in different exons, thus minimising the risk of genomic DNA amplification 
and great care was taken to ensure that pseudogenes [18] are not amplified (supplementary data). 
Primer annealing temperatures ranged from 56.2 to 57.9 °C. 
Table 7. Primer and probe sequences used in the Metasin assay.  
Marker Hydrolysis probe  
Amplicon 
length 
Forward primer 5' to 3' Reverse primer 5' to 3' 
PBGD 1 ctcctgaactccagatgcggga 92 tgtggtgggaaccagctc tgttgaggtttccccgaat 
CK19 2 cagccagacgggcattgtcg 128 cagccactactacacgaccatc caaacttggttcggaagtcatc 
MGB 3 ctctggctgccccttattggag 69 ctcccagcactgctacgc ggattgattgtcttggaaatcaca 
Dye label: 1 cyan 500; 2 LC610; 3 LC670. 
4.7. RT-PCR Assay 
All PCR assays were performed on the SmartCycler 2.0 (Cepheid, Sunnyvale, CA, USA) with the 
aim of generating quantification cycles (Cqs) for Metasin that are close to those of the Genesearch test. 
Hence, optimisation matrices of primer (1.0–2.5 μM) and probe (0.05–0.1 μM) concentrations, 
together with optimised RNA concentrations were used to identify the optimal combination of 
oligonucleotide and RNA concentrations. The final protocol was a one-tube, two-step protocol that 
makes use of the dual RNA- and DNA-dependent polymerase activities of Tth DNA polymerase. 
Reactions used 4 μL RNA in a total reaction volume of 25 μL with final primer and probe 
concentrations of 2.5 μM and 1.0 μM, respectively and were run in parallel by a Biomedical Scientist 
(BMS) (PSG) and a research fellow (SAR). The RT step of the two-step protocol was carried out for  
4 min at 60 °C, followed by 40 cycles of 95 °C 10 s, target-specific annealing temperature for  
10 s and a polymerisation step at 72 °C for 10 s. The details of the reporting of the RT-qPCR 
experiments described here are compliant with the MIQE guidelines [32].  
4.8. Positive and Negative Controls 
Every run contained at least one positive control and one negative control. The positive control 
consisted of a sample of RNA that had previously tested positive for all three mRNA targets; the 
negative control was an RNA sample that had previously tested negative for CK19 and MGB, but 
positive for PBGD.  
4.9. PCR Efficiency and Copy Number Calculations 
The MCF7 (ATCC) cell line was grown in Eagle’s MEM culture medium supplemented by 10% 
FBS in 5% CO2 [33]. On reaching 70–80 percent confluence, cells were trypsinised, harvested and 
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counted. One million cells were used for RNA extractions using the modified RNA extraction protocol 
described above. RNA was two-fold serially diluted, 4 μL of each serially diluted RNA was used with 
the Metasin assay and resulting Cqs were plotted against the log of RNA concentration. This was 
repeated five times and results are shown in Figure 3A. 
To correlate Cq with copy number, linearised plasmids specifying the amplicons for CK19, MGB 
or PBGD were prepared by TiBMOL BIOL at 4 × 109 copies/μL. They were ten-fold serially diluted, 
amplified using the Metasin assay and resulting Cq values were plotted against the log of the copy 
numbers (Figure 3B). 
4.10. Cut-Off Cq Value for CK19 and MGB for Positive and Negative Nodes 
A scatter plot was prepared plotting Metasin Cq values for CK19 vs. MGB of all nodes. Each point 
on the scatter plot was also correlated with histology. Vertical and horizontal lines were drawn 
selecting the best Cq value for both markers which incorporated all the true positive nodes without 
creating any false-positive node results. Once these cut-offs were established, their sensitivities along 
with the confidence intervals and specificities were calculated as well as their negative and positive 
predictive values. The cut off Cq value for each marker was chosen so as to minimise the number of 
false positive results.  
The same method was used to determine the optimum cut-offs for micrometastases  
and macrometastases. 
4.11. Statistical Analysis 
The data were shown to be non-parametric, with the Kolmogorov-Smirnoff test of distribution 
indicating a uniform but non-Gaussian distribution (Z value = 2.187, p value < 0.0001). Cq values 
were separated according to positive and negative nodes and comparison of Genesearch and Metasin 
for PBGD, CK19 and MGB was performed using Spearman correlation tests. The null hypothesis was 
defined as there not being any significant difference between Genesearch and Metasin Cq values for 
each of the three markers. 
4.12. CK19 and MGB IHC on Breast Cores 
All needle cores of the cases analysed in the retrospective cases at Harlow were stained for CK19 
and MGB evaluated for staining characteristics. These cores were scored positive or negative by two 
experienced Consultant Histopathologists (EA & MLS). The Consultant Histopathologist reviewing 
the slides were “blind” to the outcome of the Metasin and GeneSearch data.  
5. Conclusions  
The Metasin assay is fast fit for purpose with a discordance rate below 4% ready for implementation in 
the intraoperative setting for the assessment of sentinel nodes. 
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Supplementary Information 
Figure S1. PCR product identification. PCR products from individual PCR reactions were 
size fractionated using a 4 percent gels (Nusieve) and prepared in TBE buffer. Ten  
micro-litres of PCR product was run in each lane and gel stained with ethidium bromide 
and the gel was photographed under UV light. The upper panel (A) illustrate the 
fluorescence of the PCR products from PCR amplification of PBGD (Lanes 1–3), CK19 
(4–6) and MGB (lanes 7 & 8). Lanes 9 to 13 are PCR reactions from known positive cases. 
The molecular weight markers (MW = phix Hae III digest markers) are indicated to the left 
of the panel A and also within the gel (lane 7). The size markers correspond to CK19 with 
128 base pairs (bp), PBGD 92 bp and MGB 69 bp. The (B) illustrates the PCR bands 
corresponding to each of the relevant genes (labelled (PBGD, CK19 & MGB). A schematic 
is shown to the right (last panel) illustrating the band sizes corresponding each of the  
3 genes with their expected band sizes to the right of the schematic. The penultimate panel 
illustrates the 10 μL of the Metasin BLN PCR product.  
 
Figure S2. CK19 Pseudogene Alignments. CK19 Pseudogene alignments [18] (A) 
Sequence alignment of members of the CK19 gene family. CK19. Primer alignment  
(B & D) shows several mismatches with both the forward and reverse primer binding 
sequences. The detection probe sequence (C) also has a number of mismatches with 
pseudogene target sequences. 
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Table S1. Summary of discordant case analysis. Metasin vs. GeneSearch and Metasin vs. Histology—Discordance analysis. 
Case No Metasin GeneSearch 
BLNA 
Histopathology Node-based 
Concordance or 
Discordance 
Case-based-
Concordance/discordance 
Notes 
Initial Analysis Deeper 
Levels 
1 16837 Negative Macro-
metastasis 
Macro-metastasis NA Macro-metastasis 
Discordant 
Macro-metastasis 
Discordant 
1 2008 case-earliest batch of cases (? RNA degradation) 
Macro detected in one of 2 slices given for histology in 2 
levels only. Not present in third slice or in deeper level 
2 7587B Negative Negative Macro-metastasis NA  Macro-metastasis 
Discordant 
Concordant 2 Another lymph node from this case showed both 
histological and molecular evidence of metastatic  
disease-hence not a true discordant case.  
3 Macro-metastasis 3 mm tumour in 1 slice 
3 12395 Negative Negative 3Macro-metastasis  
3 mm in 1 slice 
NA Macro-metastasis 
Discordant 
Macro-metastasis 
Discordant 
3 Macro-metastasis 3 mm tumour in 1 slice 
4 12082 Positive 
Micromet 
Negative Negative Negative Micro-metastasis 
Discordant 
Micro-metastasis 
Discordant 
4 Micro met MGB 31.5, Metasin Cq for CK19 is 29.9 
(Veridex cut off is 30) 
6 9041B 6 Positive 
Micromet 
6 Positive 
Micromet 
Negative Negative Micro-metastasis 
Discordant 
Micro-metastasis 
Discordant 
6 9041B Cp MGB is 30.4, Metasin 29.8. Positive 
independent of Metasin on GeneSearch BLN Assay  
7 8489 Positive 
Micromet 
Positive 
Micromet 
Negative 7 ITC Micro-metastasis 
Discordant 
7 ITC’s present in 
axillary clearance 
7 ITCs seen in deeper levels and in axillary clearance 
specimen. Positive independent of Metasin on GeneSearch 
BLN Assay  
8 10931B Positive 
Macro 
Positive 
Micromet 
Negative Negative Micro/Macro 
metastasis 
Discordant 
Micro/Macro metastasis 
Discordant 
8 Positive independent of Metasin on GeneSearch BLN 
Assay  
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